Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of August 2026. The report addresses a corporate governance event regarding the company's Annual General Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice and does not contain financial statements or performance data.
Material Changes
There are no material financial changes reported. The primary event is the adjournment of the Annual General Meeting of Shareholders originally scheduled for August 6, 2026, due to a lack of required legal quorum.
Outlook and Management Commentary
Management has announced that the Annual General Meeting will reconvene on August 7, 2026, at 3:00 p.m. Israel time at the Company's office in Tel Aviv, in accordance with the Amended and Restated Articles of Association. No specific business outlook, risks, or unusual items were disclosed in this text.
Key Facts for Investors
- The Annual General Meeting scheduled for August 6, 2026, was adjourned due to insufficient quorum.
- The meeting is rescheduled for August 7, 2026, at 3:00 p.m. Israel time.
- This filing incorporates by reference multiple prior Registration Statements on Forms S-8 and F-3.
- No financial performance data is included in this specific filing.